Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors.

De Falco V, Guarino V, Malorni L, Cirafici AM, Troglio F, Erreni M, Pelicci G, Santoro M, Melillo RM.

Oncogene. 2005 Sep 15;24(41):6303-13.

PMID:
15940252
2.

The neuron-specific Rai (ShcC) adaptor protein inhibits apoptosis by coupling Ret to the phosphatidylinositol 3-kinase/Akt signaling pathway.

Pelicci G, Troglio F, Bodini A, Melillo RM, Pettirossi V, Coda L, De Giuseppe A, Santoro M, Pelicci PG.

Mol Cell Biol. 2002 Oct;22(20):7351-63.

3.

XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.

Lodyga M, De Falco V, Bai XH, Kapus A, Melillo RM, Santoro M, Liu M.

Oncogene. 2009 Feb 19;28(7):937-49. doi: 10.1038/onc.2008.447. Epub 2008 Dec 8.

PMID:
19060924
4.

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase.

Knauf JA, Kuroda H, Basu S, Fagin JA.

Oncogene. 2003 Jul 10;22(28):4406-12.

PMID:
12853977
5.

RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.

Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M.

Mol Endocrinol. 2003 Jul;17(7):1382-94. Epub 2003 May 8.

PMID:
12738763
6.

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I.

Mol Cell Biol. 2001 Jul;21(13):4177-87.

7.

Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.

Mercalli E, Ghizzoni S, Arighi E, Alberti L, Sangregorio R, Radice MT, Gishizky ML, Pierotti MA, Borrello MG.

Oncogene. 2001 Jun 14;20(27):3475-85.

8.

Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases.

Hwang ES, Kim DW, Hwang JH, Jung HS, Suh JM, Park YJ, Chung HK, Song JH, Park KC, Park SH, Yun HJ, Kim JM, Shong M.

Mol Endocrinol. 2004 Nov;18(11):2672-84. Epub 2004 Aug 5.

PMID:
15297606
9.

The Rai (Shc C) adaptor protein regulates the neuronal stress response and protects against cerebral ischemia.

Troglio F, Echart C, Gobbi A, Pawson T, Pelicci PG, De Simoni MG, Pelicci G.

Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15476-81. Epub 2004 Oct 19.

10.

RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.

De Falco V, Castellone MD, De Vita G, Cirafici AM, Hershman JM, Guerrero C, Fusco A, Melillo RM, Santoro M.

Cancer Res. 2007 Jan 1;67(1):381-90.

11.

Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.

Kim YR, Byun HS, Won M, Park KA, Kim JM, Choi BL, Lee H, Hong JH, Park J, Seok JH, Kim DW, Shong M, Park SK, Hur GM.

BMC Cancer. 2008 May 23;8:144. doi: 10.1186/1471-2407-8-144.

12.

The Shc family protein adaptor, Rai, negatively regulates T cell antigen receptor signaling by inhibiting ZAP-70 recruitment and activation.

Ferro M, Savino MT, Ortensi B, Finetti F, Genovese L, Masi G, Ulivieri C, Benati D, Pelicci G, Baldari CT.

PLoS One. 2011;6(12):e29899. doi: 10.1371/journal.pone.0029899. Epub 2011 Dec 29.

13.

Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.

Maeda K, Murakami H, Yoshida R, Ichihara M, Abe A, Hirai M, Murohara T, Takahashi M.

Biochem Biophys Res Commun. 2004 Oct 8;323(1):345-54.

PMID:
15351743
14.

The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M.

Am J Pathol. 2004 Aug;165(2):511-21.

15.

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA.

Cancer Res. 2008 Jun 1;68(11):4183-91. doi: 10.1158/0008-5472.CAN-08-0413.

16.

Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells.

Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M, Ringel MD.

Mol Carcinog. 2004 Oct;41(2):98-107.

PMID:
15378648
17.

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

Couto JP, Almeida A, Daly L, Sobrinho-Simões M, Bromberg JF, Soares P.

PLoS One. 2012;7(10):e46869. doi: 10.1371/journal.pone.0046869. Epub 2012 Oct 2.

18.

The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins.

Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, Pelicci PG, Pierotti MA.

Oncogene. 1994 Jun;9(6):1661-8.

PMID:
8183561
19.

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.

Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A.

Cancer Res. 2006 Jun 15;66(12):6280-7. Retraction in: Cancer Res. 2018 Dec 15;78(24):6907.

20.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

PMID:
15316058

Supplemental Content

Support Center